We are excited to announce the Dynavax DV3-MEL-01 study for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) is now open to recruitment.  Head and Neck cancer includes cancer of the tongue, gum, mouth, salivary glands, tonsils, pharynx, nasal cavity and larynx.  This study is testing a new therapy in combination with Keytruda (pembrolizumab) immunotherapy.  More information … Continue reading Head and Neck study Now Open